# Control of Rheumatoid Arthritis (RA) by oral tolerance

Submission date	Recruitment status  No longer recruiting	Prospectively registered	
18/07/2002		☐ Protocol	
Registration date	Overall study status Completed	Statistical analysis plan	
18/07/2002		[X] Results	
Last Edited	Condition category	Individual participant data	
04/10/2007	Musculoskeletal Diseases		

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Ernest Choy

#### Contact details

Academic Department of Rheumatology GKT School of Medicines King's College Hospital (Dulwich) East Dulwich Grove London United Kingdom SE22 8PT +44 (0)20 7346 6446

# Additional identifiers

Protocol serial number S0523

# Study information

Scientific Title

### Study objectives

Not provided at time of registration

# Ethics approval required

Old ethics approval format

# Ethics approval(s)

Not provided at time of registration

# Study design

Randomised controlled trial

# Primary study design

Interventional

# Study type(s)

Treatment

# Health condition(s) or problem(s) studied

Rheumatoid arthritis

#### **Interventions**

Patients were randomly assigned to receive either 0.05 mg, 0.5 mg or 5 mg daily of bovine type II collagen (CII) or placebo for six months

# Intervention Type

Drug

#### **Phase**

**Not Specified** 

# Drug/device/biological/vaccine name(s)

Bovine type II collagen

#### Primary outcome(s)

Not provided at time of registration

#### Key secondary outcome(s))

Not provided at time of registration

# Completion date

01/01/2000

# **Eligibility**

# Key inclusion criteria

- 1. RA patients aged over 18 and fulfilling the 1987 American College of Rheumatology (ACR) criteria for the diagnosis of RA were entered into the study after giving their written informed consent.
- 2. Patients must have had the disease at least two years and have failed at least one Slow Acting

### Anti-Rheumatic Drug (SAARD)

3. All the patients had to have active arthritis defined by the presence of three out of four clinical criteria: three or more swollen joints, six or more tender joints, early morning stiffness over 45 minutes and Erythrocyte Sedimentation Rate (ESR) over 28 mm/h. Oral steroid treatment was permitted if the dose was more than 10 mg/day

## Participant type(s)

**Patient** 

# Healthy volunteers allowed

No

# Age group

**Not Specified** 

#### Sex

**Not Specified** 

# Key exclusion criteria

Not provided at time of registration

### Date of first enrolment

01/01/1998

#### Date of final enrolment

01/01/2000

# Locations

#### Countries of recruitment

United Kingdom

England

Study participating centre
Academic Department of Rheumatology
London
United Kingdom
SE22 8PT

# Sponsor information

# Organisation

Arthritis Research Campaign (ARC) (UK)

# **ROR**

https://ror.org/02jkpm469

# Funder(s)

# Funder type

Charity

# Funder Name

Arthritis Research Campaign (UK)

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/09/2001		Yes	No